Literature DB >> 6732072

Image and flow cytometric analysis of DNA content in breast cancer. Relation to estrogen receptor content and lymph node involvement.

C J Cornelisse, H R de Koning, A J Moolenaar, C J van de Velde, J S Ploem.   

Abstract

A comparative flow-cytometric and image-cytometric study was performed on 166 human breast cancers. Parallel measurements of 67 cases showed a good correlation between the DNA indices measured with each of the techniques. However, minor ploidy abnormalities were detected with flow cytometry. Only with this technique about 70% of the tumors appeared to be aneuploid. DNA profiles obtained with image cytometry frequently contained DNA values above the modal G2 value of the tumor. At least part of these broadly scattered DNA profiles resulted from multiploid tumors, as was found with flow cytometry. The mean percentage of cells with DNA contents exceeding the modal G0G1 value in image-cytometric DNA profiles (non- G0G1 cells) appeared to be highest in aneuploid lymph-node-positive (N+) tumors and lowest in near-diploid lymph-node-negative (N-) tumors. Near-diploid tumors were more frequently (70%) estrogen receptor positive (ER+) than were aneuploid tumors (50%), whereas highly aneuploid tumors with low or negative ER contents tended to be N+. Tumors with a high percentage of non- G0G1 cells value were predominantly estrogen-receptor negative (ER-).

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732072

Source DB:  PubMed          Journal:  Anal Quant Cytol        ISSN: 0190-0471


  10 in total

1.  Comparison of image analysis and flow cytometric determination of cellular DNA content.

Authors:  C Cope; D Rowe; L Delbridge; J Philips; M Friedlander
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

2.  Prognostic value of nuclear DNA content in breast cancer in relation to tumor size, nodal status, and estrogen receptor content.

Authors:  A von Rosen; L E Rutqvist; J Carstensen; A Fallenius; L Skoog; G Auer
Journal:  Breast Cancer Res Treat       Date:  1989-01       Impact factor: 4.872

3.  Ploidy studies in adenomatous polyps of the colon.

Authors:  F Whitehead; L R Jarvis; J M Skinner; R Whitehead
Journal:  J Clin Pathol       Date:  1985-11       Impact factor: 3.411

4.  Nuclear DNA content and prognosis in human breast cancer: a static cytophotometric study.

Authors:  J Harvey; N de Klerk; I Berryman; G Sterrett; M Byrne; J Papadimitriou
Journal:  Breast Cancer Res Treat       Date:  1987       Impact factor: 4.872

5.  Sequential determination of immunocytochemical estrogen receptor and nuclear DNA content in fine needle biopsies from breast carcinoma.

Authors:  C B Pestana; N Donozo; A J Pinto; P C de Almeida; G M Machado-Santelli
Journal:  Breast Cancer Res Treat       Date:  1991-09       Impact factor: 4.872

6.  DNA ploidy and S-phase fraction in medullary carcinoma of the breast--a flow cytometric analysis using archival material.

Authors:  L Pedersen; J K Larsen; I J Christensen; A Lykkesfeldt; S Holck; T Schiødt
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

7.  Prognostic relevance of DNA content in childhood renal tumours.

Authors:  S Kumar; H B Marsden; R A Cowan; J M Barnes
Journal:  Br J Cancer       Date:  1989-02       Impact factor: 7.640

8.  Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer.

Authors:  D J Horsfall; W D Tilley; S R Orell; V R Marshall; E L Cant
Journal:  Br J Cancer       Date:  1986-01       Impact factor: 7.640

9.  DNA analysis by flow cytometry, response to endocrine treatment and prognosis in advanced carcinoma of the breast.

Authors:  A D Baildam; J Zaloudik; A Howell; D M Barnes; L Turnbull; R Swindell; M Moore; R A Sellwood
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

10.  Spectral morphometric characterization of breast carcinoma cells.

Authors:  I Barshack; J Kopolovic; Z Malik; C Rothmann
Journal:  Br J Cancer       Date:  1999-03       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.